AAM
ANIK icon

Advisors Asset Management’s Anika Therapeutics ANIK Stock Holding History

Advisors Asset Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,924
Closed -$241K – 1575
2019
Q2 		$241K Sell
5,924
-285
-5% -$10.4K ﹤0.01% 1149
2019
Q1 		$188K Sell
6,209
-74
-1% -$2.53K ﹤0.01% 1216
2018
Q4 		$211K Sell
6,283
-232
-4% -$8.37K ﹤0.01% 1190
2018
Q3 		$275K Sell
6,515
-333
-5% -$13.2K ﹤0.01% 1182
2018
Q2 		$219K Sell
6,848
-472
-6% -$19.4K ﹤0.01% 1232
2018
Q1 		$381K Sell
7,320
-574
-7% -$32.4K 0.01% 1111
2017
Q4 		$426K Buy
7,894
+2,145
+37% +$119K 0.01% 1109
2017
Q3 		$333K Buy
+5,749
New +$301K 0.01% 1154

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Advisors Asset Management's ANIK Position: Q3 2019 in Review

Advisors Asset Management sold out of Anika Therapeutics (ANIK) in Q3 2019, closing a stake of 5,924 shares — an estimated $241K sold.

Advisors Asset Management first reported a position in ANIK in Q3 2017 and held it in 8 quarters. The position peaked at $426K in Q4 2017. 194 funds tracked by Wall St. Rank hold ANIK as of Q3 2019.

  • Advisors Asset Management reported no remaining Anika Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Advisors Asset Management sold 5,924 Anika Therapeutics shares in Q3 2019, an estimated $241K.
  • Advisors Asset Management first reported a position in Anika Therapeutics in Q3 2017 and held it in 8 quarters.
  • Advisors Asset Management's Anika Therapeutics position peaked at $426K in Q4 2017.
  • 194 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2019.

Based on Advisors Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.